AbCellera Biologics Inc.
ABCLNASDAQHealthcare● Active
$5.40
$-0.22(-3.86%)
Market Cap$1.6B
P/E Ratio—
52W High$6.79
52W Low$2.33
AbCellera Biologics Inc. (ABCL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABCL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.14
Est. -$0.22 · +36.4%
Revenue
$0.01B
Est. $0.01B · +53.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
ABCL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.17 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.22 | -$0.14 | +36.4% | $0.01B | $0.01B | +53.6% |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$0.18 | -$0.03 | +83.3% | $0.04B | $0.01B | +572.9% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.17 | -$0.19 | -11.8% | $0.01B | $0.01B | +41.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.17 | -$0.12 | +29.4% | $0.02B | $0.01B | +168.6% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.17 | -$0.15 | +11.8% | $0.00B | $0.01B | -42.1% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.15 | -$0.11 | +26.7% | $0.01B | $0.01B | -33.4% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -$0.14 | -$0.17 | -21.4% | $0.01B | $0.01B | -14.2% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$0.22
EPS Surpr.
+36.4%
Revenue
$0.01B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
-$0.03
EPS Est.
-$0.18
EPS Surpr.
+83.3%
Revenue
$0.04B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.17
EPS Surpr.
-11.8%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.17
EPS Surpr.
+29.4%
Revenue
$0.02B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.17
EPS Surpr.
+11.8%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.15
EPS Surpr.
+26.7%
Revenue
$0.01B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
-$0.17
EPS Est.
-$0.14
EPS Surpr.
-21.4%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.20 | $-0.15 | 1 |
| Q3 FY2027 | $-0.28 | $-0.20 | $-0.14 | 1 |
| Q2 FY2027 | $-0.27 | $-0.20 | $-0.14 | 1 |
| Q1 FY2027 | $-0.26 | $-0.19 | $-0.14 | 1 |
| Q4 FY2026 | $-0.22 | $-0.16 | $-0.12 | 1 |
| Q3 FY2026 | $-0.15 | $-0.13 | $-0.11 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +36.4% | $5.24 | $5.25 | +0.19% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +83.3% | $3.03 | $3.22 | +6.27% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -11.8% | $4.69 | $4.53 | -3.41% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +29.4% | $4.12 | $4.24 | +2.91% |
| ▲ Q2 FY2025 | May 8, 2025 | +11.8% | $2.01 | $2.01 | +0.00% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +26.7% | $2.92 | $2.92 | +0.00% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -21.4% | $2.73 | $2.89 | +5.86% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +13.3% | $2.76 | $2.85 | +3.26% |
Q2 FY2026+0.19%
Report Date
May 11, 2026
EPS Beat/Miss
+36.4%
Price Before
$5.24
Price After
$5.25
Q1 FY2026+6.27%
Report Date
Feb 24, 2026
EPS Beat/Miss
+83.3%
Price Before
$3.03
Price After
$3.22
Q4 FY2025-3.41%
Report Date
Nov 6, 2025
EPS Beat/Miss
-11.8%
Price Before
$4.69
Price After
$4.53
Q3 FY2025+2.91%
Report Date
Aug 7, 2025
EPS Beat/Miss
+29.4%
Price Before
$4.12
Price After
$4.24
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
+11.8%
Price Before
$2.01
Price After
$2.01
Q1 FY2025+0.00%
Report Date
Feb 27, 2025
EPS Beat/Miss
+26.7%
Price Before
$2.92
Price After
$2.92
Q4 FY2024+5.86%
Report Date
Nov 4, 2024
EPS Beat/Miss
-21.4%
Price Before
$2.73
Price After
$2.89
Q3 FY2024+3.26%
Report Date
Aug 6, 2024
EPS Beat/Miss
+13.3%
Price Before
$2.76
Price After
$2.85
Avg Beat Reaction+2.10%
Avg Miss Reaction+1.23%
Beat Rate6 / 8 quarters
Largest Move+6.27% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABCL ends December
AbCellera Biologics Inc. (ABCL) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.14 — beating the analyst consensus of $-0.22 by +36.4%. ABCL has beaten EPS estimates for 2 consecutive quarters. The next ABCL earnings date is expected around September 1, 2026.
Each quarter, investors track ABCL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABCL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABCL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABCL earnings · 5 questionsAbCellera Biologics Inc.'s next earnings report is expected around September 1, 2026. ABCL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABCL historically reports after market close (AMC).
ABCL earnings datewhen is ABCL earningsABCL next earnings datewhen does ABCL report earningsABCL earnings calendar
▸ Source: FMP · AbCellera Biologics Inc. SEC filings · US GAAP · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026